Efficacy and Safety of Ustekinumab in Patients with Active Systemic Lupus Erythematosus: Results Through 2 Years of an Open-Label Extension in a Phase 2 Study
J Rheumatol. 2021. Epub ahead of print
Effective treatment options for disease control in SLE are limited, resulting in a high unmet need for effective therapies in this disease area to reduce morbidity and mortality, and improve tolerability.
To this end, van Vollenhoven, et al. evaluated the long-term efficacy and safety of ustekinumab through 2 years in patients with SLE, with promising results.